533 related articles for article (PubMed ID: 29643855)
1. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
Front Immunol; 2018; 9():631. PubMed ID: 29643855
[TBL] [Abstract][Full Text] [Related]
2. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
Jin B; Ding K; Pan J
Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
[TBL] [Abstract][Full Text] [Related]
3. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.
Förster A; Grotha SP; Seeger JM; Rabenhorst A; Gehring M; Raap U; Létard S; Dubreuil P; Kashkar H; Walczak H; Roers A; Hartmann K
Allergy; 2015 Jul; 70(7):764-74. PubMed ID: 25833810
[TBL] [Abstract][Full Text] [Related]
4. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
5. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
[TBL] [Abstract][Full Text] [Related]
6. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.
Bandara G; Falduto GH; Luker A; Bai Y; Pfeiffer A; Lack J; Metcalfe DD; Olivera A
Front Immunol; 2023; 14():1078958. PubMed ID: 37025992
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
[TBL] [Abstract][Full Text] [Related]
10. Usage of sphingosine kinase isoforms in mast cells is species and/or cell type determined.
Dillahunt SE; Sargent JL; Suzuki R; Proia RL; Gilfillan A; Rivera J; Olivera A
J Immunol; 2013 Mar; 190(5):2058-67. PubMed ID: 23359503
[TBL] [Abstract][Full Text] [Related]
11. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
12. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P
Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739
[TBL] [Abstract][Full Text] [Related]
13. Molecular defects in mastocytosis: KIT and beyond KIT.
Bibi S; Langenfeld F; Jeanningros S; Brenet F; Soucie E; Hermine O; Damaj G; Dubreuil P; Arock M
Immunol Allergy Clin North Am; 2014 May; 34(2):239-62. PubMed ID: 24745672
[TBL] [Abstract][Full Text] [Related]
14. Mastocytosis: from a Molecular Point of View.
Komi DEA; Rambasek T; Wöhrl S
Clin Rev Allergy Immunol; 2018 Jun; 54(3):397-411. PubMed ID: 28725969
[TBL] [Abstract][Full Text] [Related]
15. KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells.
Chan EC; Bai Y; Bandara G; Simakova O; Brittain E; Scott L; Dyer KD; Klion AD; Maric I; Gilfillan AM; Metcalfe DD; Wilson TM
Exp Hematol; 2013 Oct; 41(10):870-881.e2. PubMed ID: 23743299
[TBL] [Abstract][Full Text] [Related]
16. Distinct signalling pathways for mutated KIT(V560G) and KIT(D816V) in mastocytosis.
Chan IJ; Kasprowicz S; Tharp MD
Clin Exp Dermatol; 2013 Jul; 38(5):538-44. PubMed ID: 23777495
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.
Bibi S; Arock M
Immunol Allergy Clin North Am; 2018 Aug; 38(3):527-543. PubMed ID: 30007468
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis.
Toledo MAS; Gatz M; Sontag S; Gleixner KV; Eisenwort G; Feldberg K; Hamouda AEI; Kluge F; Guareschi R; Rossetti G; Sechi AS; Dufva OMJ; Mustjoki SM; Maurer A; Schüler HM; Goetzke R; Braunschweig T; Kaiser A; Panse J; Jawhar M; Reiter A; Hilberg F; Ettmayer P; Wagner W; Koschmieder S; Brümmendorf TH; Valent P; Chatain N; Zenke M
Blood; 2021 Apr; 137(15):2070-2084. PubMed ID: 33512435
[TBL] [Abstract][Full Text] [Related]
19. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
20. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.
Jin Y; Lu Z; Cao K; Zhu Y; Chen Q; Zhu F; Qian C; Pan J
Mol Cancer Ther; 2010 Jan; 9(1):211-23. PubMed ID: 20053766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
